Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. - Wikidata - wikimedia - TriplyDB

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

http://www.wikidata.org/entity/Q37597024

about

Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice.Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.Safety considerations with fenofibrate/simvastatin combination.Glucose targets for preventing diabetic kidney disease and its progression.Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats.

P2860

Q35115268-037DE363-4335-4CBA-86E3-1BA1656FB83C Q36745091-8D4807BE-1DB8-4317-9B5D-7E4C72EA3E58 Q37653029-1D306DD6-FB77-4EC3-9F86-82D9AB7D64B7 Q38383033-0B65352A-B446-4B7B-8398-5519767C985D Q38541832-4D98965F-4A77-4CFB-B274-3E82977EFEEA Q38736800-33DED834-9EC9-49E3-8B9F-EE4763C9E098 Q49484413-7D5C9241-00B0-4D2A-86F7-C32449625EFE

P2860

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

http://www.wikidata.org/entity/Q37597024

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Paradoxical reduction in HDL-C ...... betes: the ACCORD Lipid Trial.

@en

Paradoxical reduction in HDL-C ...... betes: the ACCORD Lipid Trial.

@nl

type

label

Paradoxical reduction in HDL-C ...... betes: the ACCORD Lipid Trial.

@en

Paradoxical reduction in HDL-C ...... betes: the ACCORD Lipid Trial.

@nl

prefLabel

Paradoxical reduction in HDL-C ...... betes: the ACCORD Lipid Trial.

@en

Paradoxical reduction in HDL-C ...... betes: the ACCORD Lipid Trial.

@nl

P1433

Q37597024-BD7208EC-7C7D-4E53-BE5B-B213750AE821

P1476

Q37597024-9BFEE889-9DCA-4417-8671-C2EFB02A3559

P2093

Q37597024-44B041F3-D524-4CE4-9DD3-CB0378B0835F

Q37597024-572FE25E-3FF6-48FC-B624-05189042AEDE

Q37597024-664744B8-5A94-499C-B970-7F091455910E

Q37597024-B7BEAE11-D636-46FB-A4BD-B1864679EE8E

Q37597024-C28AA5C4-41F4-49DF-8107-8D22ADD5A7AE

Q37597024-C5A402F4-5966-438B-8790-912992530499

Q37597024-D0FF3D17-F572-4F01-9E1E-4CD7786F8091

Q37597024-E21E38F3-B605-4BA5-A538-52FC20CDC376

Q37597024-E5E246CF-80E0-4004-B783-8BD0F56EEE64

Q37597024-E9945E67-E87C-451B-B7A0-8C5941FC8A4C

P2860

Q37597024-02727919-9B35-47A6-9A32-0163BB13CE60

Q37597024-032AF874-B5BB-4193-9624-F13D54D392A3

Q37597024-1269775F-C488-4E7C-B02E-7157BF002136

Q37597024-30216F5B-BD9A-43BA-AAF3-55C70FE85651

Q37597024-303413E6-9492-437A-9DDE-0235AEF5C155

Q37597024-3374B514-2DB2-43AD-A617-4CE59C2FA0A0

Q37597024-3F73FAB4-F977-49D3-B0B2-C8BE8F0E2136

Q37597024-49DEAFF5-2AC1-42BF-B7D8-76ACFC00112D

Q37597024-53BB398B-0D85-4910-B111-7CCD4E32B3A6

Q37597024-5B5C671D-EACC-48C3-89DB-770914473AA0

P304

Q37597024-67CD128B-9AFE-4A3C-A0D8-D80589AFD737

P31

Q37597024-E27039D8-F1E8-4863-8A1B-E9E25896873F

P356

Q37597024-07763BD8-8C7B-4949-AA90-837627DA254B

P407

Q37597024-D56CAF2F-7884-431C-891C-D3C253DC935C

P433

Q37597024-3901D747-FAE8-424E-913F-3F420333D486

P478

Q37597024-635EE026-A621-4E8F-A9EA-86D40D3C969C

P50

Q37597024-0F8040F4-DE60-4C2C-9323-F8F43B7AB0F9

Q37597024-8548EEB7-979F-45D5-BBF7-97871940DBF1

P577

Q37597024-BC56C0BF-F8E9-4F31-B47C-E4B097A4E27C

P5875

Q37597024-AB5F761A-0D4C-498F-818F-BB92ED6970EC

P698

Q37597024-A3D92E97-9CF7-4AC7-89A3-247D68BA23D0

P921

Q37597024-C25B38C4-0931-4DCA-9B42-DDE28240E2A2

P932

Q37597024-AA6C6A6F-1F24-4ABF-A368-A2D559EF8B8A

P356

P1433

P1476

Paradoxical reduction in HDL-C ...... abetes: the ACCORD Lipid Trial

@en

P2093

Daniel Weiss

http://www.w3.org/2001/XMLSchema#string

Debra L Simmons

http://www.w3.org/2001/XMLSchema#string

Faramarz Ismail-Beigi

http://www.w3.org/2001/XMLSchema#string

Henry N Ginsberg

http://www.w3.org/2001/XMLSchema#string

John R Crouse

http://www.w3.org/2001/XMLSchema#string

Laura C Lovato

http://www.w3.org/2001/XMLSchema#string

Lawrence A Leiter

http://www.w3.org/2001/XMLSchema#string

Marshall B Elam

http://www.w3.org/2001/XMLSchema#string

Peter E Linz

http://www.w3.org/2001/XMLSchema#string

Rex W Force

http://www.w3.org/2001/XMLSchema#string

P2860

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis

Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study

Effects of intensive glucose lowering in type 2 diabetes

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Differentiating members of the thiazolidinedione class: a focus on safety.

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Iatrogenic severe depression of high-density lipoprotein cholesterol.

P304

686-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0790

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Vasilios Papademetriou

P577

2013-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259113904

http://www.w3.org/2001/XMLSchema#string

P698

24296848

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3931389

http://www.w3.org/2001/XMLSchema#string